Poraibi 銷售預測與市場規模分析（2034 年）

推動 Poraibi 成長的關鍵因素

1. 擴大市場佔有率並增加新患者數量

• Poraivy（ Polatuzumab vedotin ）是羅氏公司開發的抗體藥物複合體（ADC），它正在改變瀰漫性大B細胞淋巴瘤（DLBCL）市場的格局，尤其是在一線和復發/難治性患者中。
• 在關鍵臨床試驗中表現出的顯著生存獲益的支持下，隨著 Poraivy 被納入標準治療方法，新患者的數量正在增加。
• 羅氏針對血液學和腫瘤學領域的針對性商業策略，加上加強對醫生的教育和納入指南，正在加速學術醫院和社區癌症中心對相關技術的應用。

2. 主要適應症的擴展

• DLBCL 一線治療：對於先前未接受治療的 DLBCL 患者，Porivy 和 R-CHOP 的聯合治療已成為 R-CHOP 的主要替代方案，並得到了優異的無惡化存活期結果的支持。
• 復發/難治性瀰漫性大B細胞淋巴瘤：繼續使用苯達莫司汀和Rituximab（Pola-BR）聯合治療，支持其在後續治療中繼續使用。
• 更廣泛的 B 細胞淋巴瘤：正在進行的研究正在評估 Poraivy 在其他侵襲性和非侵襲性 B 細胞非何傑金氏淋巴瘤中的療效。
• 研發管線和聯合療法：與新型藥物和免疫療法的聯合應用可能會進一步擴大 Poraivy 在各個治療領域的作用。

3. 地理擴張

• 全球商業發展：Poraibee 已核准在美國、歐洲和日本等主要市場上市。
• 新興市場：羅氏成熟的腫瘤治療平台和不斷擴大的先進淋巴瘤治療方案支持其向新興市場擴張。
• 亞太地區成長：淋巴瘤發生率上升、診斷率提高以及生物製藥的普及可望推動亞太地區加速成長。

4. 新適應症的核准

• 核准用於第一線 DLBCL：Poraivy 與 R-CHP聯合治療用於治療以前未接受過治療的 DLBCL 的核准，大大擴展了治療選擇。
• 擴大適應症的優勢：在初始治療和復發/難治性治療領域核准，增強了羅氏的競爭優勢，並使其收入來源多元化。
• 監管進展：正在進行的研究有望完善和擴大特定 DLBCL 亞組的適應症。

5. 對瀰漫性大B細胞淋巴瘤治療的需求勢頭強勁

• 侵襲性淋巴瘤方面存在巨大的未滿足需求：儘管旨在根治性，但相當一部分 DLBCL 患者會復發或對一線治療無反應，導致對改進的治療方法的持續需求。
• 令人信服的臨床結果：無惡化生存期的改善和各風險亞組的一致療效正在推動治療量的增加。
• 指引採納：納入主要臨床指引正在推動全球處方量的持續成長。

6. 競爭差異化與市場趨勢

• 定向ADC 機制：Poraibee 將其細胞毒性有效載荷直接遞送至表達 CD79b 的 B 細胞，使其有別於傳統化療和裸抗體。
• 最佳化化療平台：在第一線治療中以長春新鹼取代現有標準療法，可以克服其療效限制。
• 向精準醫療的轉變：對標靶治療和生物標記驅動治療的日益重視，鞏固了 Poraibi 在侵襲性淋巴瘤領域的地位。
• 真實世界數據 (RWE) 的角色日益擴大：核准後的真實世界數據增強了付款者和處方方對 Porivee 長期風險效益的信心。

波拉伊比的最新進展

在POLARIX III期臨床試驗中，Poraivy合併R-CHOP方案在初治瀰漫性大B細胞淋巴瘤（DLBCL）患者中展現出優於標準治療方案R-CHOP的無惡化生存期。核准作為一線治療方案與R-CHOP合併使用，顯著鞏固了Poraivy的市場地位。羅氏持續公佈真實世界數據和亞組分析結果，證實Poraivy在不同患者群體中均具有持久的療效。目前正在進行的臨床計畫正在探索Poraivy與其他聯合治療療法以及在早期治療中的應用，進一步強化其作為侵襲性B細胞淋巴瘤關鍵標靶治療的地位。

《Poraivy銷售預測及市場規模分析（2034）》報告全面深入地分析了Poraivy在七大主要市場（英國、四個歐盟國家（德國、法國、義大利和西班牙）、英國、瑞士和荷蘭）的核准適應症（瀰漫性大B細胞淋巴瘤）以及潛在適應症（美國淋巴瘤、慢性淋巴性白血病白血病、非何傑金氏淋巴瘤）。本報告核准分析了Poraivy在2020年至2034年研究期間，在七大主要市場（美國、四個歐盟國家（德國、法國、義大利和西班牙）、英國和日本）的現有用途、預期市場准入以及在已獲批和潛在適應症中的臨床表現。此外，報告還詳細描述了Poraivy在核准和潛在適應症的應用。這份Poraivy市場報告深入分析了Poraivy的銷售預測、作用機制、劑量和給藥途徑，以及研發和其他開發活動，包括監管里程碑。此外，該報告還詳細分析了Poraivy過去和當前的市場表現，評估了其未來市場前景（包括對七個主要國家已通過核准和潛在適應症的Poraivy市場進行預測分析），並提供了SWOT分析、分析師觀點、市場競爭對手的全面概述，以及針對每種適應症的其他新興治療方法的概述。該報告還對Poraivy的銷售額及其市場促進因素進行了預測分析。

波利維藥物概要

Polavi（Polatuzumab vedotin）是由基因泰克（羅氏）公司開發的抗體藥物複合體（ADC）。它是一種人源化單株抗體，靶向B細胞特異性抗原CD79b，並透過蛋白酶可切割的連接子與微管破壞劑單甲基澳瑞他汀E（MMAE）共用價連接。 Polavi與惡性B細胞上的CD79b結合後被內化，並釋放MMAE，從而抑制細胞分裂並誘導細胞凋亡。與傳統化療相比，Polavi對淋巴瘤中增殖的B細胞具有選擇性細胞毒性，減少了對健康組織的影響。 2019年，Polavi獲得FDA核准，用於治療先前接受過兩種或兩種以上核准後復發或難治性瀰漫性大B細胞淋巴瘤（DLBCL），需與苯達莫司汀和Rituximab昔單抗聯合治療。 2023年，此藥物核准昔Rituximab、Cyclophosphamide、多柔比星和潑尼松（R-CHP方案）聯合治療用於治療未經治療的瀰漫性大B細胞淋巴瘤（DLBCL）或高等級B細胞淋巴瘤（IPI評分≥2）。本藥每21天靜脈注射（1.8 mg/kg），需預先服用藥物。本報告提供了Porivee的銷售情況、成長抑制因素和促進因素、上市後狀況以及多項適應症的核准情況等資訊。

Poribee 市場報告的範圍

本報告深入分析了以下內容：

• Porivy 的全面產品概述，包括其作用機制 (MoA)、產品說明、劑量和給藥方法、已核准適應症（例如，瀰漫性大 B 細胞淋巴瘤）的研究和開發活動，以及潛在適應症（例如，濾泡性淋巴瘤、慢性淋巴性白血病、非何傑金氏淋巴瘤、里氏症）。
• 本市場報告詳細介紹了 Poribee 的監管里程碑和其他發展活動。
• 該報告還重點介紹了 Porivee 在美國、歐洲和日本的成本估算和區域差異、已報告和估計的銷售額，以及已通過核准和潛在適應症的研發活動。
• Poribee 的市場報告還涵蓋了專利資訊、學名藥上市及其對降低成本的影響。
• Poraibee 市場報告涵蓋了截至 2034 年已通過核准和潛在適應症的當前和預測銷售額。
• 此外，也全面介紹了每種適應症中新興的後期治療方法。
• Poraiby 市場報告還包含 SWOT 分析，分析師對 Poraiby 在已通過核准和潛在適應症方面的看法。

調查方法：

這份Poribee市場報告主要基於從內部資料庫、一手和二手研究以及DelveInsight產業專家團隊的內部分析中獲得的數據和資訊。二手資訊和資料來自各種印刷和非印刷來源，例如搜尋引擎、新聞網站、全球監管機構網站、行業期刊、白皮書、雜誌、書籍、行業協會、行業入口網站以及對現有資料庫的存取。

DelveInsight 的 Poribee 分析觀點

• 對波拉伊比市場的詳細評估

這份Poraivy市場預測報告詳細評估了美國在七個主要市場（美國、四個歐盟國家（德國、法國、義大利和西班牙）、英國和日本）的市場狀況，涵蓋其核准的適應症－瀰漫性大B細胞淋巴瘤，以及潛在的適應症－濾泡性淋巴瘤、慢性淋巴性白血病、英國非何傑金氏淋巴瘤和里B細胞淋巴瘤。報告的這一部分提供了Poraivy截至2034年的當前銷售數據和預測銷售數據。

• 波萊比的臨床評價

Poraiby 市場報告提供了 Poraiby已通過核准和潛在適應症的臨床試驗資訊，包括研究干預、研究條件、實驗狀況、開始和完成日期。

波拉伊比的競爭格局

本報告深入分析了該領域的競爭對手和市售產品，並概述了新興產品及其預計上市日期，這些產品將在市場上造成激烈的競爭。

Poraibee市場潛力及收入預測

• Porivee及其在主要適應症中的預期市場規模
• Poraibee 的預期銷售潛力（銷售尖峰時段預測）
• Porivee定價策略與報銷狀態

Poribee的競爭訊息

• 在研競爭藥物數量（研發管線分析）
• 與現有療法相比，Poraibee 的市場定位
• 與競爭對手相比，Poraibi 的優勢和劣勢

Poribee的監管和商業里程碑

• Porivee的關鍵監管核准和預計上市時間
• 商業合作、授權協議和併購活動

波萊比的臨床分化

• 與現有藥物相比，Poraiby 具有更優的療效和安全性。
• Poraibi的獨特賣點

Poribee 市場報告要點

• 未來幾年，隨著 Poraibee 的廣泛應用、處方箋的增加以及在多種免疫適應症中的更廣泛應用，其市場格局可能會發生變化，這將推動市場規模的成長。
• Poraibee相關企業致力於開發以治療和改善疾病狀態的新方法為重點的治療方法，評估可能影響 Poraibee 優勢的挑戰和機會。
• 其他用於治療瀰漫性大B細胞淋巴瘤的新興產品，以及濾泡性淋巴瘤、慢性淋巴性白血病、非何傑金氏淋巴瘤和里氏症等潛在適應症，預計將對Porivee構成激烈的市場競爭，而近期推出的後期治療方法預計也將對市場產生重大影響。
• 它詳細描述了監管里程碑和開發活動，以了解 Porivee 在已通過核准和潛在適應症中的當前開發情況。
• 我們分析 Poraibee 的成本、定價趨勢和市場定位，以支持免疫學領域的策略決策。
• 我們對 Porivee 到 2034 年的銷售預測數據進行了詳細分析，這將整體情況展現 Porivee 在已通過核准和潛在適應症方面的表現，從而支持您的治療組合決策流程。

目錄

第1章 報告概述

2. Poraibi 在核准的適應症（例如瀰漫性大B細胞淋巴瘤）和潛在適應症（例如濾泡性淋巴瘤、慢性淋巴性白血病、非何傑金氏淋巴瘤和里氏症候群）中的概述

• 產品詳情
• Porivee臨床開發
  • 波萊比臨床研究
  • Poraibi 臨床試驗資訊
  • 安全性和有效性
• 其他發展活動
• 產品簡介

第3章 波拉比的競爭格局（市售治療方法）

第4章 競爭格局（後期新興政策治療方法）

第5章：政策市場評估

• Porivee已通過核准和潛在適應症的市場展望
• 對七個主要國家的分析
  • Porivee在七個主要國家已通過核准和潛在適應症的市場規模
• 各國市場
  • 美國已通過核准和潛在適應症的市場規模
  • Poliby在德國的市場規模（已通過核准和潛在適應症）
  • 在英國，Porivee 的市場規模（已通過核准和潛在適應症）

第6章 Poribee 的 SWOT 分析

第7章 分析師觀點

第8章附錄

第9章 DelveInsight 服務

第10章 免責聲明

第11章 關於 DelveInsight

第12章 報告購買選項

Key Factors Driving Polivy Growth

1. Market Share Gains and New Patient Starts

• POLIVY (polatuzumab vedotin), an antibody-drug conjugate (ADC) developed by Roche, is gaining market traction in the diffuse large B-cell lymphoma (DLBCL) landscape, particularly in frontline and relapsed/refractory settings.
• New patient starts are increasing as POLIVY becomes more firmly embedded in standard treatment regimens, supported by strong survival benefits demonstrated in pivotal trials.
• Roche's targeted hematology-oncology commercial strategy, coupled with robust physician education and guideline inclusion, is accelerating adoption across academic and community oncology practices.

2. Expansion Across Key Indications

• Frontline DLBCL: POLIVY in combination with R-CHP has emerged as a key alternative to R-CHOP in previously untreated DLBCL patients, supported by superior progression-free survival outcomes.
• Relapsed/Refractory DLBCL: Continued use in combination with bendamustine and rituximab (Pola-BR) supports sustained utilization in later-line settings.
• Broader B-Cell Lymphomas: Ongoing studies are evaluating POLIVY in other aggressive and indolent B-cell non-Hodgkin lymphomas.
• Pipeline and Combination Strategies: Additional combinations with novel agents and immunotherapies may further expand POLIVY's role across treatment lines.

3. Geographic Expansion

• Global Commercial Footprint: POLIVY is approved and commercialized across major markets including the United States, Europe, and Japan.
• Emerging Markets: Expansion into emerging markets is supported by Roche's established oncology infrastructure and increasing access to advanced lymphoma therapies.
• Asia-Pacific Growth: Rising lymphoma incidence, improved diagnostic rates, and greater access to biologics are expected to support accelerated growth in Asia-Pacific regions.

4. New Indication Approvals

• Frontline DLBCL Approval: Regulatory approval of POLIVY in combination with R-CHP for untreated DLBCL significantly broadened its treatment landscape.
• Label Expansion Strength: Approvals in both frontline and relapsed/refractory settings enhance Roche's competitive positioning and diversify revenue streams.
• Regulatory Momentum: Ongoing studies may support additional label refinements or expansions into specific DLBCL subpopulations.

5. Strong DLBCL Volume Momentum

• High Unmet Need in Aggressive Lymphomas: Despite curative intent, a significant proportion of DLBCL patients relapse or fail first-line therapy, sustaining demand for improved regimens.
• Compelling Clinical Outcomes: Improved progression-free survival and consistent benefit across risk subgroups are driving strong treatment volumes.
• Guideline Inclusion: Incorporation into major clinical guidelines is reinforcing sustained prescription momentum globally.

6. Competitive Differentiation and Market Trends

• Targeted ADC Mechanism: POLIVY delivers a cytotoxic payload directly to CD79b-expressing B cells, differentiating it from conventional chemotherapy and naked antibodies.
• Chemotherapy Backbone Optimization: Replacement of vincristine in frontline regimens addresses efficacy limitations of historical standards of care.
• Shift toward Precision Oncology: Growing emphasis on targeted and biomarker-driven therapies supports POLIVY's positioning in aggressive lymphomas.
• Increasing Role of Real-World Evidence (RWE): Post-approval RWE is reinforcing payer and prescriber confidence in POLIVY's long-term benefit-risk profile.

Polivy Recent Developments

POLIVY's market position was significantly strengthened following regulatory approvals for frontline use in combination with R-CHP, based on the POLARIX Phase III trial, which demonstrated superior progression-free survival compared with standard R-CHOP in previously untreated DLBCL patients. Roche has continued to report consistent real-world and subgroup analyses supporting the durability of benefit across patient populations. Ongoing clinical programs are exploring POLIVY in additional combination regimens and earlier treatment settings, reinforcing its role as a cornerstone targeted therapy in aggressive B-cell lymphomas.

"Polivy Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Polivy for approved indication like Diffuse large B cell lymphoma; as well as potential indications like Follicular lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; and Richter's syndrome in the 7MM. A detailed picture of Polivy's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Polivy for approved and potential indications. The Polivy market report provides insights about Polivy's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Polivy performance, future market assessments inclusive of the Polivy market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Polivy sales forecasts, along with factors driving its market.

Polivy Drug Summary

Polivy (polatuzumab vedotin) is an antibody-drug conjugate (ADC) developed by Genentech (Roche) comprising a humanized monoclonal antibody targeting CD79b-a B-cell-specific antigen covalently linked via a protease-cleavable linker to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Upon binding to CD79b on malignant B cells, it internalizes, releases MMAE intracellularly, inhibits cell division, and induces apoptosis, selectively delivering cytotoxicity to proliferating B cells in lymphomas while sparing healthy tissues more than traditional chemotherapy. FDA-approved in 2019 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after >=2 prior therapies in combination with bendamustine and rituximab, and expanded in 2023 for previously untreated DLBCL or high-grade B-cell lymphoma (IPI >=2) with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP), it is administered intravenously every 21 days (1.8 mg/kg) under premedication. The report provides Polivy's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Polivy Market Report

The report provides insights into:

• A comprehensive product overview including the Polivy MoA, description, dosage and administration, research and development activities in approved indications like Diffuse large B cell lymphoma; as well as potential indications like Follicular lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; and Richter's syndrome.
• Elaborated details on Polivy regulatory milestones and other development activities have been provided in Polivy market report.
• The report also highlights Polivy's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Polivy market report also covers the patents information, generic entry and impact on cost cut.
• The Polivy market report contains current and forecasted Polivy sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Polivy market report also features the SWOT analysis with analyst views for Polivy in approved and potential indications.

Methodology:

The Polivy market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Polivy Analytical Perspective by DelveInsight

• In-depth Polivy Market Assessment

This Polivy sales market forecast report provides a detailed market assessment of Polivy for approved indication like Diffuse large B cell lymphoma; as well as potential indications like Follicular lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; and Richter's syndrome in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Polivy sales data uptil 2034.

• Polivy Clinical Assessment

The Polivy market report provides the clinical trials information of Polivy for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Polivy Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Polivy Market Potential & Revenue Forecast

• Projected market size for the Polivy and its key indications
• Estimated Polivy sales potential (Polivy peak sales forecasts)
• Polivy Pricing strategies and reimbursement landscape

Polivy Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Polivy Market positioning compared to existing treatments
• Polivy Strengths & weaknesses relative to competitors

Polivy Regulatory & Commercial Milestones

• Polivy Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Polivy Clinical Differentiation

• Polivy Efficacy & safety advantages over existing drugs
• Polivy Unique selling points

Polivy Market Report Highlights

• In the coming years, the Polivy market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Polivy companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Polivy's dominance.
• Other emerging products for Diffuse large B cell lymphoma; as well as potential indications like Follicular lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; and Richter's syndrome are expected to give tough market competition to Polivy and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Polivy in approved and potential indications.
• Analyse Polivy cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Polivy sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Polivy in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Polivy? How strong is Polivy's clinical and commercial performance?
• What is Polivy's clinical trial status in each individual indications such as Diffuse large B cell lymphoma; as well as potential indications like Follicular lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; and Richter's syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Polivy Manufacturers?
• What are the key designations that have been granted to Polivy for approved and potential indications? How are they going to impact Polivy's penetration in various geographies?
• What is the current and forecasted Polivy market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Polivy in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Polivy for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Polivy? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. Polivy Overview in approved indications like Diffuse large B cell lymphoma; as well as potential indications like Follicular lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; and Richter's syndrome

• 2.1. Product Detail
• 2.2. Polivy Clinical Development
  • 2.2.1. Polivy Clinical studies
  • 2.2.2. Polivy Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Polivy Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Polivy Therapies)

5. Polivy Market Assessment

• 5.1. Polivy Market Outlook in approved and potential indications
• 5.2. 7MM Analysis
  • 5.2.1. Polivy Market Size in the 7MM for approved and potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. Polivy Market Size in the United States for approved and potential indications
  • 5.3.2. Polivy Market Size in Germany for approved and potential indications
  • 5.3.3. Polivy Market Size in France for approved and potential indications
  • 5.3.4. Polivy Market Size in Italy for approved and potential indications
  • 5.3.5. Polivy Market Size in Spain for approved and potential indications
  • 5.3.6. Polivy Market Size in the United Kingdom for approved and potential indications
  • 5.3.7. Polivy Market Size in Japan for approved and potential indications

6. Polivy SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

List of Tables

• Table 1: Polivy, Clinical Trial Description, 2023
• Table 2: Polivy, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Polivy's pricing and cost Assumptions
• Table 6: Polivy's Sales Analysis in the 7MM, in USD million (2020-2034)
• Table 7: Polivy Market Size in the US, in USD million (2020-2034)
• Table 8: Polivy Market Size in Germany, in USD million (2020-2034)
• Table 9: Polivy Market Size in France, in USD million (2020-2034)
• Table 10: Polivy Market Size in Italy, in USD million (2020-2034)
• Table 11: Polivy Market Size in Spain, in USD million (2020-2034)
• Table 12: Polivy Market Size in the UK, in USD million (2020-2034)
• Table 13: Polivy Market Size in Japan, in USD million (2020-2034)

List of Figures

• Figure 1: Polivy's Sales Analysis in the 7MM, USD million (2020-2034)
• Figure 2: Polivy Market Size in the United States, USD million (2020-2034)
• Figure 3: Polivy Market Size in Germany, USD million (2020-2034)
• Figure 4: Polivy Market Size in France, USD million (2020-2034)
• Figure 5: Polivy Market Size in Italy, USD million (2020-2034)
• Figure 6: Polivy Market Size in Spain, USD million (2020-2034)
• Figure 7: Polivy Market Size in the United Kingdom, USD million (2020-2034)
• Figure 8: Polivy Market Size in Japan, USD million (2020-2034)